论文部分内容阅读
目的:对曲美他嗪治疗冠心病心力衰竭的治疗效果效果进行探讨研究。方法:选择2015年12月-2016年12月间我院接收的100例冠心病心力衰竭患者,依据所采取两种不同治疗方法划分成两个组别,对照组50例采取常规治疗,研究组50例采取常规治疗结合曲美他嗪治疗,治疗后观察比较两组治疗效果。结果:研究组总有效率96.0%,对照组总有效率74.0%,两组之间差异明显(P<0.05);研究组LVEF(50.3±3.4)%、LVESD(35.1±1.9)mm、LVEDD(55.3±3.1)mm,对照组(44.7±2.3)%、(38.5±2.1)mm、(58.1±3.2)mm,两组之间差异明显(P<0.05)。结论:曲美他嗪应用于治疗冠心病心力衰竭效果明显,具备临床推广价值。
Objective: To investigate the effect of trimetazidine treatment of heart failure in patients with coronary heart disease. Methods: From December 2015 to December 2016, 100 patients with CHD who received coronary heart disease in our hospital were divided into two groups according to the two different treatment methods taken. The control group of 50 patients were treated with conventional therapy. The study group Fifty patients were treated with trimetazidine combined with conventional therapy. After treatment, the therapeutic effects were compared between the two groups. Results: The total effective rate was 96.0% in the study group and 74.0% in the control group, with significant difference between the two groups (P <0.05). The LVEF (50.3 ± 3.4)%, LVESD 55.3 ± 3.1 mm in the control group, 44.7 ± 2.3% in the control group, 38.5 ± 2.1 mm in the control group and 58.1 ± 3.2 mm in the control group. There was significant difference between the two groups (P <0.05). Conclusion: Trimetazidine is effective in treating heart failure due to coronary heart disease and has clinical value.